

Recommendations from the Combined Immunization Schedule Work Group for the 2025 Immunization Schedules for Children/Adolescents and Adults

Sybil Cineas, MD, FAAP, FACP (ACIP Combined Immunization WG Chair) Nanda Issa, MD (CDC Co-Lead) Patricia Wodi, MD (CDC acting Co-Lead)

ACIP Meeting October 24, 2024

The Combined Immunization Schedules WG:

- Updates the immunization schedules annually
 - Child and adolescent schedule (for ages 18 years or younger)
 - Adult schedule (for ages 19 years or older)
- Harmonizes the child/adolescent and adult schedules

Monoclonal antibod	7	Abbreviation(s)	Trade name(s)	How to	use the c	hild and	adolesce	nt immun	nization
Respiratory syncytial v	virus monocional antibody (Nirseviru	ab) RSV-mAb Abbreviation(s)	Beyfortus** Trade name(s)	schedul	le				
COVID-19		TvCOV-mRNA	Comimaty*/Pfizer- BioNTech COVID-19 Vaccine Spikevax*/Moderna COVID-19 Vaccine	1 Determine recommended vaccine by ace	2 Determine recommended interval for catch	3 Assess need for additional recommended	4 Review vaccine types, frequencies,	5 Review contraindications and precautions	6 Review new or updated ACIP quidance
		1vCOV-aPS	Novavax COVID-19 Vaccine	(Table 1)	up vaccination (Table 2)	vaccines by medical	intervals, and considerations	for vaccine types	(Addendum)
Dengue vaccine		DEN4CYD	Dengvaxia*		(more Zj	condition or	for special	(represented)	
Diphtheria, tetanus, ar	nd acellular pertussis vaccine	DTaP	Daptacel* Infants*			other indication (Table 3)	situations (Notes)		
Haemophilus Influenzo	ar type b vaccine	Hib (PRP-T)	ActH8*	-					
		HIS (PRP.OMP)	Hibertx* PerformHIR*	Recommender	d by the Advisory (Committee on Im	munization Pract	ices (www.cdc.gov	v/vaccines/acto
									an Academ
	tubA hal	Immuniza	tion Co	hadu			UNITED	STATES	Michwives
	or older	mmumza	uon se	neuu	le		20	25	ocal health
					and the second second				ocarnearth
ult Immunizatio	on Schedule*								
ult Immunizatio		name(s)	How t	to use the	e adult im			dule	i) at
dult Immunizatio	Abbreviation(s) Tracle	name(s) naty/Pfizer-BioNTech COVID–19 Va ax/Moderna COVID–19 Vaccine		ne 🤈 Assess n	eocl 3 Roview	waccine 🛕 Rev	dem 5	dule Review new or updated	i) at
dult Immunizatio	Abbreviation(s) Trade	naty/Pfizer-BioNTech COVID-19 Va	ccine 1 Determin recomme vaccinati	ne ended 2 Assess n for addit recomm	eed 3 Review tonal sended freque	dosing dosing and and	riew traindications precautions	Review new or updated ACIP guidance	i) at 18 p.m. ET,
dult Immunizatio	Abbreviation(s) Trade 1vCOV-mRNA Comin Spikev 1vCOV-aPS Novav	naty/Pfizer-BioNTech COVID-19 Va rax/Moderna COVID-19 Vaccine	ccine 1 Determin recomme	ne ended Assess n for addit recomm vacchat	eed 3 Review fonal types, ended freque kons by interva	dosing 4 Rev dosing and nciesand and distand for	view traindications 5	Review new or updated	
	Abbreviation(s) Trade 1vCOV-mRNA Comin Spikev 1vCOV-aPS Novav	naty/Pfizer-BioNTech COVID-19 Va rax/Moderna COVID-19 Vaccine ax COVID-19 Vaccine 8, Hilberix, PedvaxHIB	ccine 1 Determin recomme vaccinati by age	ne ended Assess n for addit recomm vacchat	eed 3 Review fonal types, ended freque lons by Interva conside n or specia	vvaccine da Ras dosing nciesand and its and for ierations for (Ap 1 situations	view traindications 5 straindications 5 strained types	Review new or updated ACIP guidance	

Recom for ages

Vaccine	Abbreviation (s)	Trade name(s)	How to use the adult immunization sched						
COVID-19 vaccine	1vCOV-mRNA	Comimaty/Pfizer-BioNTech COVID-19Vaccine Spikevax/Moderna COVID-19Vaccine	recommended for additional types, dosing contraindications						
	1vCOV-aPS	Novavax COVID-19 Vaccine	vaccinations recommended frequencies and and precautions ACI						
Haemophilus influenzae type b vaccine	Hib	ActHIB, Hiberix, PedvaxHIB	by age vaccinations by intervals, and for vaccine types (Ac (Table 1) medical considerations for (Appendix)						
Hepatitis A vaccine	НерА	Havrix, Vaqta	condition or special situations						
Hepatitis A and hepatitis B vaccine	НерА-НерВ	Twintix	other indication (Notes) (Table 2)						
Hepatiltis B vaccine	НерВ	Engerix–B, Heplisav–B, PreHevbrio, Recombivax HB	(read a)						
Human papillomavirus vaccine	HPV	Gardasil 9	Recommended by the Advisory Committee on Immunization Practices (www.cdc.go						
	IIV3	Multiple	acip) and approved by the Centers for Disease Control and Prevention (www.cd						
Influenza vaccine (inactivated; egg–based)	allV3	Ruad	College of Physicians (www.acponline.org), American Academy of Family Physicians (org), American College of Obstetricians and Gynecologists (www.acog.org), American						
	HD-IV3	Fluzone High-Dose	of Nurse-Midwives (www.midwife.org), American Academy of Physician Ass						
Influenza vaccine (inactivated; celi–culture)	cclIV3	FluceIvax	org), American Pharmacists Association (www.pharmacist.com), and Society for Healt Epidemiology of America (www.shea-online.org).						
Influenza vaccine (recombinant)	RIV3	Flublok	Epidemiology of America (www.snea-online.org).						
Influenza vaccine (live, attenuated)	LAIV3	FluMist	Report						
Measles, mumps, and rubella vaccine	MMR	M-M-R IL Priorix	 Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department 						
	MenACWY-CRM	Menweo	 Clinically significant adverse events to the Vaccine Adverse Event Reporting System a www.vaers.hhs.gov or 800-822-7967 						
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-TT	MenQuadfi	Questions or comments						
	Men8-4C	8exsero	Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish						
Meningococcal serogroup B vaccine	Men8-FHbp	Trumenba	8 a.m8 p.m. ET, Monday through Friday, excluding holidays.						
Meningococcal serogroup A, B, C, W, Y vaccine	MenACWY-TT/ MenB-FHbp	Penbraya	Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.						
Mpox vaccine	Mpox	Jynneos	Helpful information						
	PCV15	Vaxneuvance	Complete Advisory Committee on Immunization Practices (ACIP) recommendations:						
Pneumococcal conjugate vaccine	PCV20	Prevnar 20	www.cdc.gow/vaccines/hcp/adp-recs/index.html • ACIP Shared Clinical Decision–Making Recommendations:						
	PCV21	Capvaxive	 www.cdc.gov/vaccines/acip/acip-scdm-faqs.html 						
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23	General Best Practice Guidelines for Immunization						
Pollovirus vaccine	IPV	Ipol	www.cdc.gov/vaccines/hcp/acip=recs/general=recs/index.html • Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html						
Respiratory syncytial virus vaccine	RSV	Abrysvo, Arexvy, mResvia	 Manual for the Surveillance of Vaccine–Preventable Diseases 						
Tetanus and diphtheria vaccine	Td	Tenivac	(including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual Sci						
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel, Boostrix	10						
Varicella vaccine	VAR	Varivax	U.S. Department of Health and Human Services Centers for Disease						
Zoster vaccine, recombinant	RZV	Shingtix	Health and Human Services						
Administer recommended vaccines if vaccination h	history is incomplete o	r unknown. Do not restart or add doses to vaccine	Centers for Disease						

Jaccines in the Ad

series if there are extended intervals between doses. The use of trade names is for identification purposes only and does no imply endorsement by the ACIP or CDC 03/01/2024



Health and Human Service ontrol and Prevention

v the Advisory Committee on Immunization Practices (www. and by the Centers for Disease Control and Prevention (www.cdc.org/) American clans (www.acponline.org), American Academy of Family Physicians (www.aafp ollege of Obstetricians and Gynecologists (www.acog.org), American College

es (www.midwife.org), American Academy of Physician Associates (www.aa armacists Association (www.pharmacist.com), and Society for Healthcare



2

an Oil cos

 The immunization schedules are primarily designed to be a tool for healthcare providers to ensure individuals get all the vaccines they need when they need them.

	for ages	nmended Child an 5 18 years or younger			mmun	izatio	n Sche	dule	20	D25		
	Monoclonal antibod Respiratory syncytial Vaccine COVID-19 Dengue vaccine	Her Immunizing Agents In the Child and Ac what menodonal antibody (Rinerimab) what menodonal antibody (Rinerimab) nd antibular personal wecche		ntzation Schedule* Trade name(s) Beyfortus* Trade name(s) Corrinary/Pfizer- Bio/Trach CoVID-19 Vacche Novaux COVID-19 Vacche Dengenat* Dengenat* Deptace!*	How to schedul 1 Determine recommended vacche by age (Table 1)		3 Assess need for additional	adolesce 4 Review vaccine types, frequencies, intervals, and considerations for special situations	nt immui 5 Review contraindication and precautions for vaccine types (Appendite)	6 Review new or updated ACIP guidance		
		ılt Immunizati	on So	hedul	9		UNITED S	25		vAraccines/acip) erican Academy , American		
for ages 19 years o	roider						201		vaapa.org), and			
accines in the Adult Immunization S	Schedule*		Concernant Concernant									
/accine	Abbreviation(s)	Trade name(s)	How	to use the a	idult imn	nunizati	on schee	dule	to the second state	and in case if the second state		
OVID-19 vaccine	1vCOV-mRNA	Comimaty/Pfizer-BioNTech COVID-19Vaccine Spikevax/Moderna COVID-19Vaccine	1 Determ	nine 2 Assess need for additional	types dosing contraindications or u d frequencies and and precautions ACI			eview new rupdated	ks to your state or local health ting System (VAERS) at			
	1vCOV-aP5	Novavax COVID-19 Vaccine	vaccin	stions recommende				CIP guidance	any system (is	Long at		
zemophilus influenzae type b vaccine	Hib	ActHIB, Hiberix, PedvaxHIB		by age vaccinations by intervals and for vaccine types (Addendum) (Table 1) medical considerations for (Appendix)								
patitis A vaccine	НерА	Havrix, Vaqta		condition or special situations						ал8 рл. ET,		
patitis A and hepatitis B vaccine	HepA-HepB	Twintx		other indicat (Table 2)								
patitis B vaccine	НерВ	Engerix–8, Heplisav–8, PreHevbrio, Recombivax HB	1140004.27									
ıman papillomavirus vaccine	HPV	Gardasil 9	Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/									
fluenza vaccine (inactivated; egg-based)	IIV3	Multiple		ac(p) and approved by the Centers for Disease Control and Prevention (www.cdc.gov). American College of Physicians (www.cp.online.org), American Academy of Family Physicians (www.adp. org), American College of Dottertricians and Gynecologists (www.acqpderectan College of College					vmendations:			
	allV3	Fluad										
	HD-IV3	Fluzone High-Dose	of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.					itions and precautions):				
fuenza vaccine (inactivated; celi–culture)	cclIV3	FluceIvax										
luenza vaccine (recombinant)	RN3	Flublok	Epidemioi	ogy of America (www.st	sea-online.org).							
luenza vaccine (live, attenuated)	LAIV3	FluMist	Report									
easles, mumps, and rubella vaccine	MMR	M-M-R IL Priorix	 Suspected 	 Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department 					Scan QR co for access online sched			
	MenACWY-CRM	Menveo	 Clinically significant adverse events to the Vaccine Adverse Event Reporting System at 					國際語識等				
eningococcal serogroups A, C, W, Y vaccine	MenACWY-TT	MenQuadfi		shins.gov or 800-822-79	m/							
	Men8-4C	Bexsero		ns or comments w.cdc.gov/cdc-info or 8	IN COC INFO (IN	0.727.4626 in	Coalirb or Scool	ch.	····· ·······························			
eningococcal serogroup B vaccine	MenB-FHbp	Trumenba					cingmin of sparte					
eningococcal serogroup A, B, C, W, Y vaccine	MenACWY-TT/ MenB-FHbp	Penbraya	8 am -8 pm. ET, Monday through Friday, excluding holidays. Download the CDC Vaccine Schedules app for providers at www.cdc.gov/accines/schedules/horps/schedule-app.html.						cano			
pox vaccine	Mpox	Imneos		and the second second	and a second second second	and opposite						
	PCV15	Vaxneuvance		Helpful information Complete Advisory Committee on Immunization Practices (ACIP) recommendations:								
eumococcal conjugate vaccine	PCV20	Prevnar 20	www.cdc/	gov/vaccines/hcp/acip-	recs/index.html		constant researchorn					
	PCV21	Capyastve		 ACIP Shared Clinical Decision–Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-fags.html 								
rumococcal polysaccharide vaccine	PPSV23	Pneumovax 23	 General Be 	st Practice Guidelines for	Immunization							
lovirus vaccine	IPV	ipol		gov/vaccines/hcp/acip-			100000					
spiratory syncytial virus vaccine	RSV	Abrysvo, Arexvy, mResvia		formation statements: v r the Surveillance of Vac			pexntml					
tanus and diphtheria vaccine	Td	Tenivac	(induding	case identification and	outbreak respons	ie):		can OR code				
tanus, diphtheria, and acellular pertussis			www.cdci	gov/vaccines/pubs/surv	/-manual		1	or access to				
coine	Tdap	Adacel, Boostrix	online schedule									
ricella vaccine	VAR	Varivax	100	U.	S. Department		2					
oster vaccine, recombinant	RZV	Shingrix		CDC	ealth and Hum	an Services	2	KH STO				

Centers for Disease

Control and Prevention

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine serie: if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply-endosrement by the ALP or CDC.

03/01/2024

- The immunization schedules reflect existing ACIP recommendations approved by the CDC director.
 - New vaccination policies are not established in the immunization schedules.

		mended Child ar 18 years or younger		olescent l	mmun	izatio	n Sche	edule	2()25			
		r Immunizing Agents in the Child and A		ounization Schedule*									
1	Monoclonal antibody	us monodonal antibody (Ninevimab)	Abbrevittion(s) RSV-mAb Abbrevittion(s) 1vCOV-mRNA	Trade name(6) Beyfortus** Trade name(6) Corninaty*/Pfzer- BioNrech (2010-19 Vaccine Spikevas*/Moderna CD/ID-19 Vaccine	How to schedul 1 Determine recommended vaccine by age	e 2 Determine recommended	hild and	4 Review vaccine types, frequencies.	nt immui	6 Review new or supdated ACIP			
	Dengue vaccine Diphtheria, tetanus, and Haamophilus influanzae	facellular pertussis vaccine	1vCOV-aPS DEN4CYD DTaP Hilb (PRP-T)	Novavax COVID-19 Vaccine Dengvasia* Daptacel* Infarric* ActhUI*	(Table 1)	up vaccination (Table 2)	vaccines by medical condition or other indication (Table 3)	intervals, and considerations for special	for vaccine types (Appendix)	(Addendum)			
ecommend r ages 19 years o res in the Adult Immunization	or older	ult Immunizat					20	25	cdc.gov), Am ww.aafp.org Jollege of Nu apa.org), and	rse-Midwives			
	Abbreviation(s)	Trade name(s)		ow to use the									
19 vaccine	1vCOV-mRNA	Comimaty/Pfizer-BioNTech COVID-19Vaccine Spikevax/Moderna COVID-19Vaccine						ig System (VAERS) at					
	1vCOV-aPS	Novavax COVID-19 Vaccine	b	Vaccineouris recommendad inequalmodania and processors recomplications by age vaccinetions by intervals and for vaccine types (Addendum) (Table 1) medical considerations (Appendix) condition or social stations						or Spanish, 8 a.m8 p.m. E			
hilus influenzoe type b vaccine	Hib	ActHIB, Hiberix, PedvaxHIB	0							som opnices			
s A vaccine	НерА	Havrix, Vaqta		condition other ind									
s A and hepatitis B vaccine	НерА-НерВ	Twintx Engerb-B, Heplisav-B, PreHevbrio,		(Table 2)									
s B vaccine	HepB	Recombivax HB											
papillomavirus vaccine	HPV	Gardasil 9	Recor	mmended by the Advisor	Committee on Ir	imunization Pra	ctices (www.cde		endations:				
	IIV3	Multiple	acip) a	Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vacci acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), Amer									
a vaccine (inactivated; egg-based)	allV3	Ruad	Colleg	College of Physicians (www.acponline.org), American Academy of Family Physicians (www.aafp. org), American College of Obstetricians and Gynecologists (www.acog.org), American College									
	HD-IV3	Fluzone High-Dose	of Nu	of Nurse–Midwives (www.midwife.org). American Academy of Physician Associates (www.aapa.				ins and precautions):					
a vaccine (inactivated; cell-culture)	cclIV3	FluceIvax		American Pharmacists Ass miology of America (www			ind Society for H	lealthcare					
a vaccine (recombinant)	RIV3	Flublok	Epide	miology of America (www	r.snea-onane.org					Scan OR co			
a vaccine (live, attenuated)	LAIV3	FluMist	Repo	rt						for access online sche			
, mumps, and rubella vaccine	MMR	M-M-R IL Priorix	the lo	Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department Clinically significant adverse events to the Vaccine Adverse Event Reporting System at www.vasrib.nc.gov or 800-822-7967									
ococcal serogroups A, C, W, Y vaccine	MenACWY-CRM	Menveo	· Canac WWW					em at	and the second se				
www.an.enogroups.m, v, w, i Vacone	MenACWY-TT	MenQuadfi		tions or comment									
ococcal serogroup B vaccine	MenB-4C	Bexsero	Contac	Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish,					B 9-356				
ococcal selogroup b vacure	MenB-FHbp	Trumenba	8 a.m	8 p.m. ET, Monday throug	h Friday, excludin	g holidays.			ca				
ococcal serogroup A, B, C, W, Y vaccine	MenACWY-TT/ MenB-FHbp	Penbraya	No.	Download the CDC Vac www.cdc.gov/vacdnes	cine Schedules ap /schedules/hcp/si	p for providers a hedule-app.htr	nt.						
raccine Mpox Jymneos He		Helpt	Helpful information										
	PCV15	Vaxneuvance		Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vacines/hcp/adp-recs/index.html				ons					
coccal conjugate vaccine	PCV20	Prevnar 20	 ACIP : 	Shared Clinical Decision-	Making Recomme	ndations:							
	PCV21	Capvaxive	WWW	"Recent address of the second processing reconstruction address www.cccl.address.cc.interactional address.cc.interactional www.cccl.address.cc.interactional www.cccl									
coccal polysaccharide vaccine	PPSV23	Pneumovax 23											
svaccine	IPV	lpol	 Vacci 	Vaccine Information statements: www.cdc.gov/vaccines/hcp/vis/index.html									
ory syncytial virus vaccine	RSV	Abrysvo, Arexvy, mResvia	 Manu 	al for the Surveillance of ding case identification a	/accine-Preventai	ble Diseases							
and diphtheria vaccine	Td	Tenivac		iding case identification a ucdc.gov/vaccines/pubs/s		nser		Scan QR code for access to					
, diphtheria, and acellular pertussis	Tdap	Adacel, Boostrix	10000	and the second second second			3	online schedule					
vaccine	VAR	Varivax											
raccine, recombinant	RZV	Shingrix	U.S. Department of Health and Human Services										
ter recommended vaccines if vaccination there are extended intervals between dos	history is incomplete of es. The use of trade nar	r unknown. Do not restart or add doses to vaccin nes is for identification purposes only and does	ne 🤇		Centers for Dise Control and Pre	ase		部系统					

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended interval between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

Re

Hepatiti

口門論理

Reason Topic is Being Presented to ACIP

• ACIP approval of the proposed schedules is necessary prior to publication

Child/Adolescent Schedule only	Both Schedules	Adult Schedule only
 American Academy of Pediatrics (AAP) National Association of Pediatric Nurse Practitioners (NAPNAP) 	 American Academy of Family Physicians (AAFP) American Academy of Physician Associates (AAPA) American College of Obstetricians and Gynecologists (ACOG) American College of Nurse- Midwives (ACNM) 	 American College of Physicians (ACP) Society for Healthcare Epidemiology of America (SHEA) American Pharmacists Association (APhA)

ACIP Members

Sybil Cineas (ACIP WG Chair) Charlotte Moser

Liaison Representatives

John Epling (AAFP) Sarah Coles (AAFP) Rhoda Sperling (ACOG) Holly Fontenot (SAHM) Amy Middleman (SAHM) Sandra Fryhofer (AMA) Sarah McQueen (AAPA) Marie-Michele Leger (AAPA) Caitlin Newhouse (AIM) Mary-Margaret Fill (CSTE) Yekatherine Rasmussen (ACP) William Schaffner (NFID) Robert Hopkins (NFID) Ken Schmader (AGS) Dana DeShon (NAPNAP) Preeti Mehrotra (SHEA) Pia Pannaraj (AAP) Kelly Goode (APhA)

Ex Officios

David Kim (OASH) Susan Farrall (OASH) Jane Kim (DVA) Uzo Chukwuma (IHS) Brittany Rizek (HRSA)

Consultants

Carolyn Bridges Diane Peterson Hank Bernstein Karen Ketner Kathleen Harriman Kevin Ault Litjen Tan Peter Szilagyi Susan Lett

CDC Co-Leads

A. Patricia Wodi Nanda Issa

• ACIP Combined Immunization Work Group — CDC Contributors:

- Akiko Wilson
- Agam Rao
- Andrew Kroger
- Amadea Britton
- David Sugerman
- Dan Filardo
- Daniella Moulia
- Donna Williams
- Emily Cartwright
- Erin Conners
- Femi Adeleke
- Hilda Razzaghi
- Holly Hill
- Jacqueline Tate
- Janell King
- Jefferson Jones

- Jennifer Collins
- JoEllen Wolicki
- Joseph Alcober
- Joshua Wong
- Katherine Fleming-Dutra
- Lakshmi Panagiotakopoulos
- Lauren Roper
- Lauri Markowitz
- Lisa Grohskopf
- Liz Velazquez
- Mary Chamberland
- Megan Wallace
- Megan Hofmeister
- Michael Melgar
- Michelle Hughes
- Min Kim

- Miwako Kobayashi
- Mona Marin
- Mona Doshani
- Paul Gastanaduy
- Sarah Kidd
- Sarah Schillie
- Susan Goldstein
- Suzanne Johnson-DeLeon
- Tara Anderson

Disclaimer

- The use of vaccine trade names is for identification purposes only and does not imply endorsement by the Centers for Disease Control and Prevention.
- The 2025 immunization schedules presented in the following slides are drafts and are therefore subject to change based on ACIP's discussion and vote.

Outline

- Harmonization between the child/adolescent and adult schedules
- Edits to all tables
- Content changes of the notes
- Content changes to the appendix listing contraindications and precautions
- Discussion and Vote